Koers Sorrento Therapeutics, Inc. Deutsche Boerse AG
Aandelen
8STN
US83587F2020
Biotechnologie & Medisch Onderzoek
Omzet 2021 | 52,9 mln. 48,53 mln. | Omzet 2022 | 62,84 mln. 57,64 mln. | Marktkapitalisatie | 411 mln. 377 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2021 | -428 mln. -393 mln. | Nettowinst (verlies) 2022 | -573 mln. -526 mln. | EV/omzet 2021 | 29,1 x |
Nettoschuld 2021 | 111 mln. 102 mln. | Nettoschuld 2022 | 84,53 mln. 77,53 mln. | EV/omzet 2022 | 7,89 x |
K/w-verhouding 2021 |
-3,2
x | K/w-verhouding 2022 |
-0,65
x | Werknemers | 949 |
Dividendrendement 2021 * |
-
| Dividendrendement 2022 |
-
| Vrij verhandelbaar | 97,77% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Henry Ji
CEO | Chief Executive Officer | 59 | 01-01-89 |
Shawn Sahebi
COO | Chief Operating Officer | - | - |
Mike A. Royal
CTO | Chief Tech/Sci/R&D Officer | 70 | 03-03-14 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Kim D. Janda
BRD | Director/Board Member | 67 | 01-04-12 |
David Lemus
BRD | Director/Board Member | 61 | 01-10-17 |
Jaisim Shah
BRD | Director/Board Member | 63 | 11-09-13 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+20,17% | 127 mld. | |
+24,67% | 117 mld. | |
+25,44% | 27,67 mld. | |
-17,74% | 20,33 mld. | |
-15,17% | 16,79 mld. | |
-15,21% | 15,63 mld. | |
+11,91% | 14,84 mld. | |
-47,10% | 14,65 mld. | |
+54,50% | 14,43 mld. |